long wait , page-11

Please read up on the company before making non-informative statements.

Lets start off with some independent analysis - RBS Morgans Report - 25th August 2010

"What is the potential?
In the US, Arixtra recorded US$251m in sales in FY10 for GSK (+30% on the pcp). ACL
earns a 50-60% share of profits from Dr Reddy?s, equating to a 30-35% effective royalty rate.
We estimate ACL will receive A$32.0m, A$32.0m, A$47.1m and A$45.2m over FY12-15."

Whilst I encourage scruitiny as a shareholder of ACL, I take it upon myself and regularly talk to PS and other investors/analysts to ensure my investment is sound and ask questions direct to the key people to ensure that we are not getting taken for a ride. I suggest that you give Alchemia a call if you have something on your chest and speak with PS.